|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Formaldehydeinduced gene expression in F344 rat nasal respiratory epithelium显示文摘 | HESTER S D BENAVIDES G B YOON L | 2003 | Toxicology2003，187，1： | 1 |
| 2 | Acute myeloblastic leukemia with hyperleukocytosis:Risk factor for early morality in induction显示文摘 | Venturu G J Hester J P Smith T L | 1998 | Am J Hematol1998，27，1： | 1 |
| 3 | Where did all the markets go?An analysis of EPA's emission trading program显示文摘 | Hahn R W Hester G L | 1989 | Yale Journal of Regulation1989，6，： | 1 |
| 4 | Marketable permits: lessons from theory and practice 显示文摘 | Hahn R W Hester G L | 1989 | Ecology Law Quarterly1989，16，： | 1 |
| 5 | Formaldehyde-induced gene expression in F344 rat nasal respiratory epithelium显示文摘 | Hester S D Benavides G B Yoon L | 2003 | Toxicology2003，187，1： | 1 |
| 6 | Formaldehyde induced gene expression in F344 rat nasal respiratory epithelium 显示文摘 | Hester S D Benavides G B Yoon L | 2003 | Toxicology2003，187，： | 1 |
| 7 | Where did all the Markets Go? An Analysis of EPA' s Emission' s Trading Program 显示文摘 | R W Hahn G L Hester | 1989 | Yale Journal on Regulation1989，6，1： | 1 |
| 8 | Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study显示文摘BACKGROUND Splanchnic vein thrombosis(SVT)is a major complication of moderate and severe acute pancreatitis.There is no consensus on whether therapeutic anticoagulation should be started in patients with acute pancreatitis and SVT.AIM To gain insight into current opinions and clinical decision making of pancreatologists regarding SVT in acute pancreatitis.METHODS A total of 139 pancreatologists of the Dutch Pancreatitis Study Group and Dutch Pancreatic Cancer Group were approached to complete an online survey and case vignette survey.The threshold to assume group agreement was set at 75%.RESULTS The response rate was 67%(n=93).Seventy-one pancreatologists(77%)regularly prescribed therapeutic anticoagulation in case of SVT,and 12 pancreatologists(13%)for narrowing of splanchnic vein lumen.The most common reason to treat SVT was to avoid complications(87%).Acute thrombosis was the most important factor to prescribe therapeutic anticoagulation(90%).Portal vein thrombosis was chosen as the most preferred location to initiate therapeutic anticoagulation(76%)and splenic vein thrombosis as the least preferred location(86%).The preferred initial agent was low molecular weight heparin(LMWH;87%).In the case vignettes,therapeutic anticoagulation was prescribed for acute portal vein thrombosis,with or without suspected infected necrosis(82%and 90%),and thrombus progression(88%).Agreement was lacking regarding the selection and duration of long-term anticoagulation,the indication for thrombophilia testing and upper endoscopy,and about whether risk of bleeding is a major barrier for therapeutic anticoagulation.CONCLUSION In this national survey,the pancreatologists seemed to agree on the use of therapeutic anticoagulation,using LMWH in the acute phase,for acute portal thrombosis and in the case of thrombus progression,irrespective of the presence of infected necrosis. | Noor J Sissingh Jesse V Groen Hester C Timmerhuis Marc G Besselink Bas Boekestijn Thomas L Bollen Bert A Bonsing Frederikus A Klok Hjalmar C van Santvoort Robert C Verdonk Casper H J van Eijck Jeanin E van Hooft Jan Sven D Mieog | 2023 | World Journal of Gastroenterology2023，29，21： | 1 |
| 9 | InhibitorkappaB kinase-beta regulates LPS-induced TNF-alpha production in cardiac myocytes through modulation of NF-kappaB p65 subunit phosphorylation显示文摘 | HALL G SINGH I S HESTER L | 2005 | Am J Physiol Heart Circ Physiol2005，289，： | 1 |
| 10 | Theory and Practice in Ecology Law Quarterly 显示文摘 | Hahn R W and Hester G L | 1999 | Implementing Domestic Tradable Permits for Environmental Protection1999，16，1： | 1 |
| 11 | Acute myeloblas- tic leukemia with hyperleukocytosis: Risk factor for early moral- ity in induction 显示文摘 | Venturu G J Hester J P Smith T L | 1998 | AmJ Hematol1998，27，1： | 1 |
| 12 | Endovascular treatment in anterior circulation stroke beyond 6.5 hours after onset or time last seen well:results from the MR CLEAN Registry显示文摘Background Randomised controlled trials with perfusion selection have shown benefit of endovascular treatment(EVT)for ischaemic stroke between 6 and 24 hours after symptom onset or time last seen well.However,outcomes after EVT in these late window patients without perfusion imaging are largely unknown.We assessed their characteristics and outcomes in routine clinical practice.Methods The Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands Registry,a prospective,multicentre study in the Netherlands,included patients with an anterior circulation occlusion who underwent EVT between 2014 and 2017.CT perfusion was no standard imaging modality.We used adjusted ordinal logistic regression analysis to compare patients treated within versus beyond 6.5 hours after propensity score matching on age,prestroke modified Rankin Scale(mRS),National Institutes of Health Stroke Scale,Alberta Stroke Programme Early CT Score(ASPECTS),collateral status,location of occlusion and treatment with intravenous thrombolysis.Outcomes included 3-month mRS score,functional independence(defined as mRS 0-2),and death.Results Of 3264 patients who underwent EVT,106(3.2%)were treated beyond 6.5 hours(median 8.5,IQR 6.9-10.6),of whom 93(87.7%)had unknown time of stroke onset.CT perfusion was not performed in 87/106(80.2%)late window patients.Late window patients were younger(mean 67 vs 70 years,p<0.04)and had slightly lower ASPECTS(median 8 vs 9,p<0.01),but better collateral status(collateral score 2-3:68.3%vs 57.7%,p=0.03).No differences were observed in proportions of functional independence(43.3%vs 40.5%,p=0.57)or death(24.0%vs 28.9%,p=0.28).After matching,outcomes remained similar(adjusted common OR for 1 point improvement in mRS 1.04,95%CI 0.56 to 1.93).Conclusions Without the use of CT perfusion selection criteria,EVT in the 6.5-24-hour time window was not associated with poorer outcome in selected patients with favourable clinical and CT/CT angiography characteristics.randomised controlled trials with lenient inclusion criteria are needed to identify more patients who can benefit from EVT in the late window. | Luuk Dekker Esmee Venema F Anne V Pirson Charles B L M Majoie Bart J Emmer Ivo G H Jansen Maxim J H L Mulder Robin Lemmens Robert-Jan B Goldhoorn Marieke J H Wermer Jelis Boiten Geert J LycklamaàNijeholt Yvo B W E M Roos Adriaan C G M van Es Hester F Lingsma Diederik W J Dippel Wim H van Zwam Robert J van Oostenbrugge Ido R van den Wijngaard on behalf of the MR CLEAN Registry investigators | 2021 | Stroke & Vascular Neurology2021，6，4： | 1 |
| 13 | Inhibitor - kappaB kinase - beta regulates LPS - induced TNF - alpha production in cardiac myocytes through modulation of NF - kappaB p65 subunit phosphorylation显示文摘 | Hall G Singh IS Hester L et at | 2005 | AmJ Physiol Heart Circ Physiol2005，289，5： | 1 |
| 14 | Inhibitor-kappa B ki- nase-beta regulates LPS-induced TNF-alpha production in cardiac myocytes through modulation of NF-kappa B p65 subunit phosphorylation 显示文摘 | Hall G Singh IS Hester L | 2005 | Am J Physiol Heart Circ Physiol2005，289，5： | 1 |
| 15 | 查看详情显示文摘 | Fevola M J Bridges J K Kellum M G Hester R D McCormick C L | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员